February 13th 2025
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.
Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears
How Have Colleges, Universities Addressed the COVID-19 Pandemic?
Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial
Concurrent Wildfire, Pandemic Hazards Test US Mental, Physical Health